Expo Hub
Siemens Healthineers Shape 23 Keynote
Hear from healthcare leaders like Dr. Jerome Adams, the 20th Surgeon General of the United States & Director of Health Equity at Purdue University, about how to address the challenges posed by cancer, how high-quality care can be brought to more patients, and how to address the workforce crisis.
1 / 0
Dr. Jerome Adams
20th surgeon general and Director of Health Equity at Purdue University
Dr. Amanda Caissie
Dalhousie University, Canada
Dr. Maxime Guye
Marseille University, France
Dr. Matilde Inglese
Hospital San Martino Genoa, Italy
Dr. Rahel Kubik
Kantonsspital Baden, Switzerland
Dr. Reena Nakra
Dr. Lal PathLabs, India
Dr. Pál Maurovich-Horvat
Semmelweis University, Hungary
Dr. Bernhard Meyer
Medizinische Hochschule Hannover, Germany
Dr. Arun J. Sanyal
Virginia Commonwealth University, United States
Serena Wee
Icon Cancer Centre, ASEAN and Hong Kong, Singapore
About this keynote
Siemens Healthineers Shape Keynote is our annual signature event. It offers a unique blend of market expertise and Siemens Healthineers innovations. The keynote provides access to the knowledge of some of the world’s most respected healthcare thought leaders and unveils exclusive Siemens Healthineers breakthroughs for the first time.
We are sharing inspiring ideas and innovative solutions for three of the biggest challenges faced by healthcare providers:
A world without fear of cancer
To create a world without fear of cancer, we explore how to make oncology care more predictive and more precise
Speakers: Serena Wee, Dr. Arun J. Sanyal, Dr. Amanda Caissie, Dr. Bernhard Meyer
Meet patients where they are
To meet patients where they are, we discuss how to reconfigure care delivery in both low and high acuity settings
Speakers: Dr. Jerome Adams, Dr. Pál Maurovich-Horvat, Dr. Maxime Guye, Dr. Matilde Inglese
Care for those who care for others
To care for those who care for others, we discover how technology can be a key part of the solution to the global healthcare workforce crisis
Speakers: Dr. Reena Nakra, Dr. Rahel Kubik
Highlight Product and Topics
Related episodes
1 / 0
Scaling healthcare access: The future of cancer care
See how local healthcare leaders and partnerships are transforming access to early diagnosis and comprehensive cancer care – shaping the future of healthcare for all.
Empowering today’s workforce for tomorrow
Discover how future-ready workplaces are helping healthcare providers attract, retain, and support their teams for long-term success.
Pioneering breakthroughs to provide healthcare access for all
See how global healthcare leaders are improving access through innovation, early diagnosis, and education to drive equitable, sustainable outcomes.
How to turn workforce challenges into opportunities
Learn how healthcare leaders are creating human-centered workplaces to address global staffing shortages and shape a more resilient future.
Siemens Healthineers Shape 22 Keynote
Ideas and innovations that help physicians make better decisions, that deliver intelligent cancer care and help providers to operate more effectively.
Siemens Healthineers Shape 21 Keynote
Gain insights about our beliefs on the future of healthcare and see us launch this year's innovations in image acquisition, laboratory diagnostics, robotics and more.
*The products are still under development and not commercially available yet. Its future availability cannot be ensured. Siemens Healthineers neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.
1510(k) Pending. Not available for sale.
2
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
3
In the U.S. the ELF Test is not for use in the diagnosis of NASH or for the staging of fibrosis. The ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events.